
|Articles|January 15, 2004
Ruboxistaurin reduces visual loss in diabetic retinopathy
New Orleans-Ruboxistaurin mesylate, a protein kinase C (PKC) beta inhibitor, reduces loss of vision in patients with moderate-ly severe to very severe nonproliferativediabetic retinopathy, researchers reported at the American Diabetes Association meet-ing here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
3
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
4
Q&A: Understanding Medicare payment shifts in eye care
5














































